Moreover, emerging results reveal potential treatment of GPR40 agonist and GLP-1RAs for intestinal diseases, including inflammatory bowel diseases (IBD), short bowel syndrome (SBS), intestinal toxicities and coeliac disease (Hunt et al., 2021). The gene discussed is FFAR1; the disease is inflammatory bowel disease.